Front Pharmacol . The Role of Interleukin-8 in Lung Inflammation and Injury: Implications for the Management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome

[tetano]

Front Pharmacol


. 2022 Jan 12;12:808797.
doi: 10.3389/fphar.2021.808797. eCollection 2021.
The Role of Interleukin-8 in Lung Inflammation and Injury: Implications for the Management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome


Maria Candida Cesta ¹ , Mara Zippoli ² , Carolina Marsiglia ¹ , Elizabeth Marie Gavioli ³ , Flavio Mantelli ¹ , Marcello Allegretti ¹ , Robert A Balk ⁴



Affiliations

• PMID: 35095519
• PMCID: PMC8790527
• DOI: 10.3389/fphar.2021.808797

Abstract

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) has resulted in the global spread of Coronavirus Disease 2019 (COVID-19) and an increase in complications including Acute Respiratory Distress Syndrome (ARDS). Due to the lack of therapeutic options for Acute Respiratory Distress Syndrome, recent attention has focused on differentiating hyper- and hypo-inflammatory phenotypes of ARDS to help define effective therapeutic strategies. Interleukin 8 (IL-8) is a pro-inflammatory cytokine that has a role in neutrophil activation and has been identified within the pathogenesis and progression of this disease. The aim of this review is to highlight the role of IL-8 as a biomarker and prognostic factor in modulating the hyperinflammatory response in ARDS. The crucial role of IL-8 in lung inflammation and disease pathogenesis might suggest IL-8 as a possible new therapeutic target to efficiently modulate the hyperinflammatory response in ARDS.

Keywords: ARDS; COVID-19; CXCR1/2; Interleukin 8 (IL-8); NETs; cytokine storm; neutrophils.